Latest News

Presentations

Whitepaper: Development of First-in-Class Novel Therapeutics Targeting MUC1-C For Solid Tumors.

News

Cancer outbreak and treatment for malignant cancer cells in a human body caused by carcinogens and genetics with a cancerous cell as an immunotherapy symbol and medical therapy as a 3D render.

Oct 1 2022

Xyone announces the grant of two NIA/SBIR grants totaling over 2.5 million usd to advance studies in Androgen dysregulation.

image1

April 1 2022

XYone congratulates Poseida Therapeutics in the start of its Phase 1 study of P-MUC1C-ALLO1 Allogenic Car-T cells.

News

Cancer outbreak and treatment for malignant cancer cells in a human body caused by carcinogens and genetics with a cancerous cell as an immunotherapy symbol and medical therapy as a 3D render.

Oct 1 2022

Xyone announces the grant of two NIA/SBIR grants totaling over 2.5 million usd to advance studies in Androgen dysregulation.

image1

April 1 2022

XYone congratulates Poseida Therapeutics in the start of its Phase 1 study of P-MUC1C-ALLO1 Allogenic Car-T cells.